Reviewing Decision Diagnostics (OTCMKTS:DECN) & HeartSciences (NASDAQ:HSCS)

Decision Diagnostics (OTCMKTS:DECN) and HeartSciences (NASDAQ:HSCS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Valuation & Earnings

This table compares Decision Diagnostics and HeartSciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A
HeartSciences	N/A	N/A	-$8.77 million	($8.30)	-0.28

Risk & Volatility

Decision Diagnostics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500.

Insider & Institutional Ownership

17.2% of HeartSciences shares are held by institutional investors. 1.8% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Decision Diagnostics and HeartSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decision Diagnostics	0	0	0	0	0.00
HeartSciences	1	0	2	0	2.33

HeartSciences has a consensus price target of $10.50, indicating a potential upside of 354.55%. Given HeartSciences’ stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Decision Diagnostics.

Profitability

This table compares Decision Diagnostics and HeartSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decision Diagnostics	N/A	N/A	N/A
HeartSciences	N/A	-528.27%	-165.66%

Summary

HeartSciences beats Decision Diagnostics on 6 of the 8 factors compared between the two stocks.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

About HeartSciences

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.